Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016–2021

Abstract

Objectives

To describe the results of a structured literature review of real-world outcomes with ixekizumab in patients with psoriasis (PsO) and/or psoriatic arthritis (PsA).

Methods

Literature databases, conference proceedings and additional sources were searched for relevant publications. Real-world studies of ≥25 ixekizumab-treated patients with PsO and/or PsA were included. Data on clinical effectiveness, treatment persistence/patterns, economic outcomes, patient-reported outcomes (PROs) and safety were extracted.

Results

Fifty-one publications were included. Most studies focused on patients with PsO, and the number of publications with a focus on PROs was low. Studies of treatment patterns found that in general, ixekizumab had similar or better persistence versus other biologics, and rates or risk of switching similar to or less than comparator drugs. Adherence to ixekizumab was high, and patients were less likely to discontinue ixekizumab than other biologics. Ixekizumab was effective in the real world, with a safety profile consistent with that reported in clinical trials.

Conclusions

Real-world use of ixekizumab in PsO and PsA is effective and safe, with generally high treatment persistence and adherence. Further work is required to determine the impact of ixekizumab on PROs in PsO, and to gather more data on real-world use of ixekizumab in PsA.

Keywords:

• Ixekizumab
• psoriasis
• psoriatic arthritis
• structured review
• real-world evidence

Acknowledgements

Richard Perry and Hannah Tomkinson from Adelphi Values Limited conducted the study on behalf of Eli Lilly and Company. The authors thank Sheridan Henness and Karen Goa (Rx Communications, Mold, UK) for medical writing assistance with the preparation of this manuscript, funded by Eli Lilly and Company.

Disclosure statement

Adam Reich has received personal and institutional fees from Abbvie, Alvotech, Amgen, AnaptysBio, Argenx, Biothera, BMS, Celgene, Celltrion, Dermira, Galderma, Inflarx, Janssen, Kiniska, Kymab, Leo Pharma, Novartis, Pfizer, Trevi Therapeutics and UCB; honoraria from Chema Rzeszow, Eli Lilly, Leo Pharma, Novartis, Sandoz and Takeda; and has participated on advisory boards for Abbvie, Galderma, Sandoz and Sanofi Aventis. Ennio Lubrano has received honoraria for conference talks from Abbvie, Janssen Cilag, Lilly, UCB, Pfizer and Novartis. Catherine Reed, Christopher Schuster, Camille Robert and Tamas Treuer are employees of Eli Lilly and Company.

Data availability statement

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

Additional information

Funding

This research was funded by Eli Lilly and Company.